Home > Publications Database > Non-hematopoietic erythropoietin splice variant is produced in the diseased human brain and confers neuroprotection. > print

001     284352
005     20260212105836.0
024 7 _ |a 10.3389/fncel.2025.1677505
|2 doi
024 7 _ |a pmid:41602576
|2 pmid
024 7 _ |a pmc:PMC12832296
|2 pmc
037 _ _ |a DZNE-2026-00123
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hartung, Theresa
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Non-hematopoietic erythropoietin splice variant is produced in the diseased human brain and confers neuroprotection.
260 _ _ |a Lausanne
|c 2025
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770812576_18492
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Erythropoietin (EPO) is a pleiotropic cytokine with important functions in neuronal development and neuroprotection, but hematopoietic effects limit the therapeutic application of EPO in neurological diseases. We discovered human endogenous EPO splice variants that are non-hematopoietic but cytoprotective. Here, we demonstrate at the single-cell level that an alternative splice variant lacking exon 3 (hS3) is expressed in the human brain and is upregulated above EPO mRNA levels in ischemic and inflammatory neurological diseases. Conversely, hS3 mRNA expression is reduced below EPO levels in neurodegenerative disease. In an oxygen-glucose deprivation (OGD) model of ischemia, a single dose of cell-free synthesized constant glycosylated active hS3 protects neuronal cultures derived from human induced pluripotent stem cells (hiPSC) and human embryonic stem cells (hESC) more effectively than EPO. We identify the D-helix as a key functional domain of hS3 and demonstrate that the neuroprotective effect is enhanced by PD29, a novel small peptide derived from the D-helix of hS3. Long-term hS3 administration increases the neuroprotective effects in the OGD model by dose-dependent differential expression of apoptosis-related protein-coding genes and long non-coding RNAs (lncRNAs). In addition, our results suggest that hS3 induces early cell cycle inhibition without impairing differentiation of hiPSC and hESC into neuronal subtypes. In conclusion, EPO splice variant hS3 is part of the endogenous neuroprotective system in the human brain with significant therapeutic potential.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a alternative splicing
|2 Other
650 _ 7 |a cell-free glycoprotein synthesis
|2 Other
650 _ 7 |a erythropoietin
|2 Other
650 _ 7 |a in situ hybridization
|2 Other
650 _ 7 |a neuroprotection
|2 Other
650 _ 7 |a oxygen glucose deprivation
|2 Other
650 _ 7 |a pluripotent stem cells
|2 Other
700 1 _ |a Freyer, Dorette
|b 1
700 1 _ |a Zemella, Anne
|b 2
700 1 _ |a Radbruch, Helena
|b 3
700 1 _ |a Weiner, January
|b 4
700 1 _ |a El-Din, Jasmin Jamal
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Meisel, Andreas
|b 6
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 7
|e Last author
|u dzne
773 _ _ |a 10.3389/fncel.2025.1677505
|g Vol. 19, p. 1677505
|0 PERI:(DE-600)2452963-1
|p 1677505
|t Frontiers in cellular neuroscience
|v 19
|y 2025
|x 1662-5102
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/284352/files/DZNE-2026-00123.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/284352/files/DZNE-2026-00123.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:284352
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811122
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-14
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-14
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT CELL NEUROSCI : 2022
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-12-04T12:35:29Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-12-04T12:35:29Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-14
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-14
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-12-04T12:35:29Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-14
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT CELL NEUROSCI : 2022
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-14
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-14
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000007
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21